Disappearance of slan-positive non-classical monocytes for diagnosis of chronic myelomonocytic leukemia with an associated inflammatory state

  title={Disappearance of slan-positive non-classical monocytes for diagnosis of chronic myelomonocytic leukemia with an associated inflammatory state},
  author={Sihem Tarfi and Bouchra Badaoui and Nicolas Freynet and Margot Morabito and Jeffie Lafosse and Andr{\'e}a Toma and Gabriel {\'E}tienne and Jean-Baptiste Micol and Ivan Sloma and Pierre Fenaux and Eric Solary and Doroth{\'e}e Selimoglu-Buet and Orianne Wagner-Ballon},
  pages={e147 - e152}
The diagnosis of chronic myelomonocytic leukemia (CMML) relies on both a persistent peripheral blood monocytosis (monocytes ≥1x10/L) and monocytes accounting for ≥10% of the white blood cell (WBC) differential count. We showed that a relative accumulation of classical monocytes (cMo: CD14CD16) ≥94% among the total peripheral blood monocytes measured by flow cytometry could help to distinguish CMML from other causes of monocytosis. Since then, the quantification of circulating monocyte subsets… Expand
Prognostic value of monocyte subset distribution in chronic myelomonocytic leukemia: results of a multicenter study
The prognostic value of the distribution of monocyte subset in the peripheral blood of CMML patients has not been explored so far and is not associated with a poor outcome. Expand
Incorporating flow cytometry and next-generation sequencing in the diagnosis of CMML. Are we ready for prime?
Together, recent investigations support integration of flow cytometry analysis of peripheral blood monocyte subsets and new generation sequencing of a panel of 20-30 recurrently mutated genes in the diagnostic work-up of CMML. Expand
Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19
It is shown that calprotectin plasma level and a routine flow cytometry assay detecting decreased frequencies of non-classical monocytes could discriminate patients who develop a severe COVID-19 form, suggesting a predictive value that deserves prospective evaluation. Expand
Chronic Myelomonocytic Leukemia Gold Jubilee
Chronic myelomonocytic leukemia (CMML) was named 50 years ago to describe a myeloid malignancy whose onset is typically insidious. This disease is now classified by the World Health Organisation as aExpand
Oligomonocytic and overt chronic myelomonocytic leukemia show similar clinical, genomic, and immunophenotypic features.
The clinicopathologic features of 40 patients with OM-CMML with well-annotated immunophenotypic and molecular data and compared them to those of 56 patients with overt CMML found similar clinical, morphological, and cytogenetic features, support the consideration of OM- CMML as a distinctive subtype of CMML. Expand
6-Sulfo LacNAc (Slan) as a Marker for Non-classical Monocytes
The features of slan+ cells are congruent with the features of CD16+ non-classical monocytes and that slan is a candidate marker for definition of non- classical monocyte. Expand
Chronic myelomonocytic leukemia diagnosis and management
Patients who are low risk but with symptoms from cytopenias or proliferative features such as splenomegaly may be treated with hypomethylating agents (HMAs) or cytoreductive therapy, respectively, with the goal of durable symptoms control. Expand
A hierarchical approach in the diagnostic workflow of chronic myelomonocytic leukemia: Pivotal role of the “Mono‐dysplasia‐score” combined with flow cytometric quantification of monocyte subsets
Three diagnostic approaches are studied: the classical morphology approach, the flow cytometry assay (quantification of monocyte subsets as described by Selimoglu‐Buet et al in 2015), and the “mono‐dysplasia‐score” also referred to as “Monoscore”. Expand
Monocyte subsets to differentiate chronic myelomonocytic leukemia from reactive monocytosis
No specific genetic abnormalities are present in CMML, and reactive monocytosis should be excluded, and an increase in classical monocytes (MO1) has been suggested as a screening tool. Expand
Genetic complexity of chronic myelomonocytic leukemia
A contemporary snapshot of the genetic complexity inherent to CMML is presented, the relationship between genotype-phenotype is explored, and a stepwise model of CMML pathogenesis and progression is presented. Expand


Clinical Utility of Classical and Nonclassical Monocyte Percentage in the Diagnosis of Chronic Myelomonocytic Leukemia
Quantification of monocyte subsets is useful in clinical practice as a diagnostic marker of CMML in blood and bone marrow specimens and a decreased percentage of nonclassical monocytes showed better sensitivity than the previously described approach. Expand
Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia.
It is concluded that an increase in the fraction of classical monocytes to >94.0% of total monocytes is a highly sensitive and specific diagnostic marker that rapidly and accurately distinguishes CMML from confounding diagnoses. Expand
Multicenter validation of the flow measurement of classical monocyte fraction for chronic myelomonocytic leukemia diagnosis
The robustness of the flow assay with limited variability of classical monocyte percentage between centers is demonstrated, validates the 94% cutoff value, and confirms its sensitivity and specificity. Expand
slan-defined subsets of CD16-positive monocytes: impact of granulomatous inflammation and M-CSF receptor mutation.
Gene expression profiling confirms that slan-negative intermediate monocytes show highest expression levels of major histocompatibility complex class II genes, whereas a differential ubiquitin signature is a novel feature of the slan approach. Expand
How I treat chronic myelomonocytic leukemia.
In the presence of excessive blasts and other poor prognostic factors, hypomethylating agents are the preferred option, even though their impact on leukemic transformation and survival has not been proved. Expand
The use of targeted sequencing and flow cytometry to identify patients with a clinically significant monocytosis.
Somatic mutations are detected at high frequency in patients referred with a monocytosis, irrespective of diagnosis, and in those without a World Health Organization-defined diagnosis, the mutation spectrum, immunophenotypic features, and OS are indistinguishable from CMML patients, and these patients should be managed as such. Expand
Accumulation of classical monocytes defines a subgroup of MDS that frequently evolves into CMML.
To the editor: Even though the diagnosis criteria of chronic myelomonocytic leukemia (CMML) have been recently revised by the World Health Organization (WHO),[1][1] recognition of this disease canExpand
The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia: Proposals by the French ‐ American ‐ British Cooperative Leukaemia Group
A statstical model is developed that confirms that CGL, aCML and CMML can be distinguished from each other with reasonable success employing five quantitative parameters and one qualitative parameter. Expand
A miR-150/TET3 pathway regulates the generation of mouse and human non-classical monocyte subset
A mechanistic link between miR-150 and TET3 as being involved in monocyte subset generation is identified, and it is shown that Tet3 knockout mice generate an increased number of non-classical monocytes. Expand
Toward a Refined Definition of Monocyte Subsets
While these cells appear to be in transition from classical to non-classical monocytes and hence may not form a distinct cell population in a strict sense, their separate analysis and enumeration is warranted in health and disease. Expand